02:56 , May 4, 2018 |  BC Innovations  |  Targets & Mechanisms

Solid hopes for T cell bispecifics

As next-generation T cell bispecifics hit the clinic, demonstrating efficacy in solid tumors could earn them a place in the immuno-oncology tool kit alongside CAR T cells and checkpoint inhibitors. T cell bispecific antibodies bring activated...
21:06 , Apr 6, 2018 |  BioCentury  |  Finance

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
18:37 , Mar 16, 2018 |  BC Week In Review  |  Clinical News

Glenmark's Ryaltris meets in Phase III for seasonal allergic rhinitis

Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) reported data from a Phase III trial in 1,180 patients with seasonal allergic rhinitis showing that twice-daily Ryaltris mometasone/olopatadine met the primary endpoint of improving average morning and evening patient-reported...
18:39 , Mar 2, 2018 |  BC Week In Review  |  Clinical News

Glenmark reports Phase IIa data for anti-OX40 mAb in atopic dermatitis

Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) reported data from a placebo-controlled Phase IIa trial in over 60 patients with moderate to severe atopic dermatitis showing that GBR 830 reduced mRNA biomarkers of disease activity, including S100...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
19:11 , Dec 22, 2017 |  BC Week In Review  |  Clinical News

Glenmark's Ryaltris meets in Phase III for perennial allergic rhinitis

Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) reported top-line data showing that twice-daily Ryaltris mometasone/olopatadine (formerly GSP 301) met the primary safety endpoint and a secondary efficacy endpoint in a Phase III trial to treat perennial allergic...
16:05 , May 4, 2017 |  BC Week In Review  |  Clinical News

Glenmark begins Ph I of Xolair biosimilar

Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) began a Phase I trial of GBR 310, a proposed biosimilar of Xolair omalizumab from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY). The trial will evaluate pharmacokinetics in healthy...
08:00 , Jan 28, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Microsomal prostaglandin E synthase-1 (PTGES; mPGES-1); prostaglandin E2 (PGE2)

Neurology INDICATION: Pain Cell culture, human blood and guinea pig studies identified PTGES inhibitors that could help treat arthritis-related pain. In in vitro enzymatic activity assays, two compounds based on different scaffolds inhibited PTGES activity with IC50...
08:00 , Jan 11, 2016 |  BC Week In Review  |  Company News

Glenmark, Roche cancer news

Glenmark and Roche confirmed that they settled a patent dispute in India related to Roche’s cancer drug Tarceva erlotinib. The companies have ceased all “relevant” patent litigation on the small molecule inhibitor of ...
07:00 , Sep 14, 2015 |  BC Week In Review  |  Clinical News

GBR 830: Phase I data

Data from Dutch Phase I trials in healthy volunteers showed that GBR 830 was well tolerated. In the next few months, Glenmark plans to start Phase II testing of GBR 830 to treat atopic dermatitis...